BioCentury | Feb 13, 2012
Company News

4P Therapeutics drug delivery news

...Former executives from Altea Therapeutics Corp. (Atlanta, Ga.) launched newco 4P Therapeutics. The company is partnering with pharmaceutical...
BioCentury | Jan 25, 2010
Company News

Altea, KAI deal

...The companies will use Altea's PassPort Transdermal Delivery System to co-develop three undisclosed protein kinase C...
...to receive worldwide rights to develop and commercialize resulting compounds. If KAI exercises its option, Altea...
...delta PKC inhibitor in Phase IIb testing to reduce myocardial injury in heart attack patients. Altea Therapeutics Corp....
BioCentury | Apr 6, 2009
Finance

Ebb & Flow

...Novo Nordisk A/S (CSE:NVO; NYSE:NVO). News on Wednesday that Amylin and Lilly received rights from Altea Therapeutics Corp....
...Delivery System to develop a transdermal version of exenatide had no effect on the stock. Altea...
BioCentury | Apr 6, 2009
Company News

Altea, Amylin, Eli Lilly deal

...Altea granted Lilly and Amylin exclusive, worldwide rights to develop and commercialize transdermal exenatide using Altea's...
...The once daily transdermal exenatide patch is in Phase I testing for Type II diabetes. Altea...
...milestones, plus royalties. Lilly and Amylin also will each make an undisclosed equity investment in Altea...
BioCentury | Apr 2, 2009
Company News

Altea in exenatide patch deal with Lilly, Amylin

...and Amylin Pharmaceuticals Inc. (NASDAQ:AMLN) exclusive, worldwide rights to develop and commercialize transdermal exenatide using Altea's...
...The once daily transdermal exenatide patch is in Phase I testing for Type II diabetes. Altea...
...milestones, plus royalties. Lilly and Amylin also will each make an undisclosed equity investment in Altea...
BioCentury | Aug 18, 2008
Company News

Altea scientific advisory board update

...engineering at the Georgia Institute of Technology; David Enscore, former SVP of product R&D at Altea...
BioCentury | Jul 7, 2008
Company News

Altea, Hospira deal

...Altea will fund certain Phase I testing, and Hospira will fund development and commercialization thereafter. Altea...
...includes an equity investment, and is eligible for $109 million in milestones, plus undisclosed royalties. Altea Therapeutics Corp....
BioCentury | Feb 18, 2008
Company News

Altea scientific advisory board update

Altea Therapeutics Corp. , Tucker, Ga. Business: Drug delivery Appointed: Richard Guy, professor of pharmaceutical sciences and head of the department of pharmacy and pharmacology at the University of Bath WIR Staff...
BioCentury | Nov 5, 2007
Clinical News

AT2391: Phase I data

...with subcutaneous injections of long-acting insulin. Data were presented at the Diabetes meeting in London. Altea Therapeutics Corp....
BioCentury | Feb 12, 2007
Company News

Altea board of directors update

Altea Therapeutics Corp. , Tucker, Ga. Business: Drug delivery Appointed: William Good, an industry consultant WIR Staff...
Items per page:
1 - 10 of 37
BioCentury | Feb 13, 2012
Company News

4P Therapeutics drug delivery news

...Former executives from Altea Therapeutics Corp. (Atlanta, Ga.) launched newco 4P Therapeutics. The company is partnering with pharmaceutical...
BioCentury | Jan 25, 2010
Company News

Altea, KAI deal

...The companies will use Altea's PassPort Transdermal Delivery System to co-develop three undisclosed protein kinase C...
...to receive worldwide rights to develop and commercialize resulting compounds. If KAI exercises its option, Altea...
...delta PKC inhibitor in Phase IIb testing to reduce myocardial injury in heart attack patients. Altea Therapeutics Corp....
BioCentury | Apr 6, 2009
Finance

Ebb & Flow

...Novo Nordisk A/S (CSE:NVO; NYSE:NVO). News on Wednesday that Amylin and Lilly received rights from Altea Therapeutics Corp....
...Delivery System to develop a transdermal version of exenatide had no effect on the stock. Altea...
BioCentury | Apr 6, 2009
Company News

Altea, Amylin, Eli Lilly deal

...Altea granted Lilly and Amylin exclusive, worldwide rights to develop and commercialize transdermal exenatide using Altea's...
...The once daily transdermal exenatide patch is in Phase I testing for Type II diabetes. Altea...
...milestones, plus royalties. Lilly and Amylin also will each make an undisclosed equity investment in Altea...
BioCentury | Apr 2, 2009
Company News

Altea in exenatide patch deal with Lilly, Amylin

...and Amylin Pharmaceuticals Inc. (NASDAQ:AMLN) exclusive, worldwide rights to develop and commercialize transdermal exenatide using Altea's...
...The once daily transdermal exenatide patch is in Phase I testing for Type II diabetes. Altea...
...milestones, plus royalties. Lilly and Amylin also will each make an undisclosed equity investment in Altea...
BioCentury | Aug 18, 2008
Company News

Altea scientific advisory board update

...engineering at the Georgia Institute of Technology; David Enscore, former SVP of product R&D at Altea...
BioCentury | Jul 7, 2008
Company News

Altea, Hospira deal

...Altea will fund certain Phase I testing, and Hospira will fund development and commercialization thereafter. Altea...
...includes an equity investment, and is eligible for $109 million in milestones, plus undisclosed royalties. Altea Therapeutics Corp....
BioCentury | Feb 18, 2008
Company News

Altea scientific advisory board update

Altea Therapeutics Corp. , Tucker, Ga. Business: Drug delivery Appointed: Richard Guy, professor of pharmaceutical sciences and head of the department of pharmacy and pharmacology at the University of Bath WIR Staff...
BioCentury | Nov 5, 2007
Clinical News

AT2391: Phase I data

...with subcutaneous injections of long-acting insulin. Data were presented at the Diabetes meeting in London. Altea Therapeutics Corp....
BioCentury | Feb 12, 2007
Company News

Altea board of directors update

Altea Therapeutics Corp. , Tucker, Ga. Business: Drug delivery Appointed: William Good, an industry consultant WIR Staff...
Items per page:
1 - 10 of 37